Title: Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials Author: Xiaochen Yang Xingjiang Xiong Guoyan Yang Jie Wang PII: S0965-2299(14)00006-5 DOI: http://dx.doi.org/doi:10.1016/j.ctim.2014.01.003 Reference: YCTIM 1304 To appear in: Complementary Therapies in Medicine Received date: 26-6-2013 Revised date: 27-10-2013 Accepted date: 6-1-2014 Please cite this article as: Yang X, Xiong X, Yang G, Wang J, Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials, Complementary Therapies in Medicine (2014), http://dx.doi.org/10.1016/j.ctim.2014.01.003 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Chinese Patent Medicine XueFu ZhuYu Capsule for the Treatment of Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials Xiaochen Yang 1#, Xingjiang Xiong 1#, Guoyan Yang 2#, Jie Wang 1* 1. Department of Cardiology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China 2. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China Abstract: Background. XueFu ZhuYu Capsule (XFZY) has been commonly used for relieving chest pain in patients with coronary heart disease (CHD). Randomized controlled trials (RCTs) on XFZY in treating unstable angina (UA) have not been systematically reviewed. Objective. This study aims to provide a PRISMA-compliant systematic review to evaluate the efficacy of XFZY in treating UA. Methods. An extensive search of 7 medical databases was performed up to June 2013. RCTs involving XFZY or combined with conventional drugs versus conventional drugs were identified. Meta-analysis was performed to evaluate the cardiovascular effects of XFZY. Rev Man 5.0 was used for data analysis. Results. 8 RCTs were included in this review. Statistical analysis of the results showed that XFZY combined with conventional drugs had significant effect on relieving angina symptoms (RR: 1.26 [1.16, 1.38]; P < 0.00001) and improving ECG (RR: 1.20 [1.04, 1.38]; P = 0.01) compared with conventional drugs alone. No severe adverse events were reported. Conclusions. XFZY combined with conventional drugs appears to have potential cardiovascular effects in treatment of UA with few adverse events. However, further rigorous designed trials are still needed. Introduction Angina pectoris, a symptom of coronary heart disease (CHD), manifests as stress-induced ischemic episodes resulting in severe chest pain [1]. When the same symptoms occur at rest or become severe, unstable angina (UA) is the diagnosis [2]. UA is an acute coronary syndrome and Corresponding author at: Department of Cardiology, Guang anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5#, Xicheng District, Beijing 100053, China. Tel.: +86 1088001817; fax: +86 1088001229. E-mail addresses: wangjie_gam@yahoo.com.cn (J. Wang) # These authors contributed equally in this paper. 1 Page 1 of 14
should be treated as an emergency. It can increase risk of acute myocardial infarction (heart attack) and severe cardiac arrhythmias which leading to sudden death [3]. Therefore, treatment should begin as soon as possible after onset of unstable angina. The ACC/AHA guidelines support anti-ischemic therapy, antiplatelet therapy and antithrombotic therapy. Anti-ischemia therapies include nitroglycerin, beta blocker, and oxygen as required. Antiplatelet therapies include aspirin, clopidogrel, and platelet glycoprotein IIb/IIIa inhibitor. Antithrombotic therapies include heparin and low-molecular-weight heparin [4-5]. Therapeutic aims are to improve quality of life by decreasing anginal attacks and to prevent myocardial infarction and death. But not all of these drugs are useful in every form of UA, and treatment is symptomatic rather than curative [6]. The other drawbacks of current anginal medications are adverse effects and drug resistance [7]. Treatment of UA with good prognosis remains a challenging clinical issue. Chinese herbal medicine (CHM) has a 3000-year-old history with unique theories for concepts of etiology and systems of diagnosis and treatment [8]. Recently, there is a growing and sustained interest in the benefits of CHM and potential drug interactions with western medications, especially for patients with UA [9-10]. CHM has been used for activating the blood and resolving stasis in clinical practice for the treatment of UA in China. Xuefu Zhuyu Tang, a famous formula for treating Xueyu (blood stagnation), consists of rehmannia root (shengdi), peach seed (taoren), Safflower (honghua), Chinese angelica (danggui), red peony root (chishao), platycodon root (jiegeng), orange fruit (zhiqiao), hare's ear root (chaihu), Sichuan lovage root (chuanxiong), two-toothed achyranthes root (niuxi), and prepared liquorice root (gancao). Xuefu Zhuyu Tang has been made into various high standard pharmaceutical preparations such as capsule, pill, tablet, granule and oral liquid. For instance, Xuefu Zhuyu Capsule (Hong Ren Tang Pharmaceutical Co., Ltd., Tianjin, China) consists of rehmannia root (shengdi) 43.24 mg, peach seed (taoren) 43.24 mg, Safflower (honghua) 43.24 mg, Chinese angelica (danggui) 43.24 mg, red peony root (chishao) 43.24 mg, platycodon root (jiegeng) 32.44 mg, orange fruit (zhiqiao) 32.44 mg, hare's ear root (chaihu) 32.44 mg, Sichuan lovage root (chuanxiong) 43.24 mg, two-toothed achyranthes root (niuxi) 21.62 mg, prepared liquorice root (gancao) 21.62 mg. The total dose is 2.4 g for one day. Experimental studies have shown that XFZY can increase coronary blood flow, improve the cardiac microcirculation, prevent platelet aggregation, and accommodate blood lipids [11-12]. Several studies published in China have reported that XFZY can enhance the effect of relieving of angina symptoms, decreasing the dosage of nitroglycerin and lessening side effects for patients with UA [13-16]. Liu et al [14] had undertaken meta-analysis of Chinese patent medicine XueFu ZhuYu capsule for the treatment of angina pectoris, which include stable and unstable angina pectoris trials together. However, the evidence supporting or disproving its cardiovascular effects is not robust. Our review presents a more vigorous attempt to examine the efficacy and safety of XFZY for patients with UA. Methods Search strategy Two authors (X. Yang and G. Yang) searched the following electronic databases: PubMed, the Cochrane Center Controlled Trials Register (2013), EMBASE (1980-2013), Chinese Biomedical Literature Database (CBM, 1978--June 2013), Chinese National Knowledge Infrastructure (CNKI, 1979-June 2013), Chinese Scientific Journal Database (VIP, 1989-June 2013), and Wanfang Med 2 Page 2 of 14
Online Database (WMOD, 1998- June 2013). The searching terms were XueFu ZhuYu, Guan xin bing (coronary heart disease), and Bu Wen Ding Xin jiao tong (unable angina pectoris). No language restriction was applied. Types of studies Randomized controlled trials that evaluate the cardiovascular effects of XFZY for UA were included. Quasi-RCTs were not considered. Types of participants The participants who suffering from and being treated for angina pectoris were included, regardless of the disease and severity. Diagnosis of UA was according to the 2002 ACCF/AHA Guideline for the Diagnosis and Management of Patients with Unstable Ischemic Heart Disease (2002 ACCF/AHA) or the International Society and Federation of Cardiology/World Health Organization (ISFC/WHO) [17-18]. We did not intend to make any restrictions on age, gender, and race. Types of interventions The medicine of treatment group was XFZY combined with conventional drugs for patients with UA regardless of manufactures, preparation form, dose and duration. The study was designed to compare the effectiveness and safety of XFZY used only or in combination with conventional drugs versus conventional drugs alone or plus placebo. Types of outcome measures The primary outcome measures were mortality due to ischemic heart disease and the incidence of a heart event (e.g. AMI, severity arrhythmia, heart failure, revascularization). The secondary outcome measures were: (1) reduction of angina symptoms (e.g. Effective symptomatic improvements should achieve at least 50% or 80% reduction in frequency of feeling angina chest pain [18]). (2) ECG improvement (e.g. Effective ECG improvements should achieve at least 0.05mV lowering at ST segment in ECG or nearly normal ECG during an exercise test [18]), and (3) quality of life [19]. The adverse events were also measured. Study selection. The titles and abstracts of potentially relevant references were identified through the literature search and reviewed independently by 2 reviewers (X. Yang, and X. Xiong) according to predefined criteria. Discrepancies regarding whether to include or exclude a study were resolved by consensus with other investigator (J. Wang). Data extraction The following data were extracted: (1) citations (authors of study, year of publication), (2) methodological information, (3) participants (sample size, age), (4) detailed information of interventions and controls, (5) outcome measures, and (6) adverse events. Two reviewers (X. Xiong, X. Yang) checked the disagreement of data extraction. Differences in data extraction were resolved by discussion. 3 Page 3 of 14
Trial quality assessment Two authors (Y. Zhang, G. Yang) independently assessed the methodological quality of included RCTs using Cochrane risk of bias tool. The qualities of included RCTs were assessed according to seven specific domains: (1) random sequence generation (selection bias), (2) allocation concealment (selection bias), (3) blinding of participants and personnel (performance bias), (4) blinding of outcome data (attrition bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) other bias. When completing each of the seven domains for a study, information was provided according to RevMan 5.0: (1) a description of included study; and (2) their judgment on the risk of bias as a consequence of this. This judgment is categorized by using one of the three answers: high risk, unclear risk and low risk. Statistical analysis Meta-analysis was performed if the intervention, control, and outcome were the same or similar. According to RevMan 5.0 provided by Cochrane Collaboration, dichotomous data were expressed as risk ratio (RR) and continuous outcomes as weighted mean difference (WMD), with their 95% confidence intervals (CI) respectively. The statistical heterogeneity was examined with the I 2 test, where I 2 values of 50% or more were considered to be indicators of a substantial level of heterogeneity. In the absence of significant heterogeneity (I 2 < 50%), we pooled data using a fixed-effect model, otherwise we using random effects model (I 2 > 50%) [20]. Result Literature search and study selection Our initial searches finally identified 610 articles according to the search strategy, among which 252 studies were excluded because of duplicated publication. After checking the abstracts, 405 articles were excluded because of non-clinical studies, with obvious error, or with study objectives different from the aim of this review, etc (Figure 1). Full texts of 53 articles were retrieved for further identification, and finally 8 RCTs [21-28] were included according to the inclusion criteria. The included RCTs were all conducted in China and published in Chinese. Characteristics of the trials included The characteristics of included RCTs were summarized in Table 1. The number of participants ranged from 28 to 50, with a total of 534 patients (265 patients in treatment groups) in the 8 studies. The age of the participants ranged from 35 years to 82 years. The studies included only interventions with XFZY plus conventional drugs versus conventional drugs alone or plus placebo. Because no RCTs of XFZY versus conventional drugs alone or plus placebo was founded. Conventional drugs referred to treatment according to the guidelines for UA, including platelet aggregation inhibitor (aspirin), nitrates, beta-blockers, calcium channel blockers, and ACE inhibitors. The total treatment duration ranged from 1 weeks to 8 weeks. Reductions in angina symptoms and improvement in ECG were the most commonly measured outcomes in the included studies. None trial adopted mortality as primary outcome. 1 trial [26] reported the quality of life of UA patients. 4 Page 4 of 14
Methodological Quality of Included Trials All of these studies indicated randomization with a single-center, parallel-design, but most of them did not describe it clearly. 2 trials [26, 28] reported that the random sequence was generated by a random digits table. None of trials describe allocation concealment and methods of assessing compliance. 1 trial [26] mentioned that they were single blind of subjects, but included no descriptions of the procedures. 1 trial [26] reported drop-out or withdraw, but none of trials had a pre-trial estimation of sample size, which indicated the lack of statistical power to ensure appropriate estimation of the therapeutic effect. Primary outcomes None trial adopted mortality as primary outcome. There was no report of ischemic heart disease and the incidence of a heart event (e.g. AMI, severity arrhythmia, heart failure, revascularization). Reduction of angina symptoms (RAS) A total of 7 trials [21-25, 27-28] with 477 patients used reduction of angina symptoms (RAS) to measure the outcome. It is showed homogeneity in the results (P=0.74, I 2 =0%). Thus, we did a quantitative data synthesis (meta-analysis) by fixed-effects model. The outcome shows a statistically significant difference in favor of the combination group of XFZY and conventional drugs (RR: 1.26 [1.16, 1.38]; P < 0.00001). It is suggested that XFZY plus conventional drugs had a better effect on relieving symptoms of angina. (Table 2). ECG improvement A total of 4 trials [22, 25, 27, 28] with 276 patients used ECG to measure the outcome. It is showed homogeneity in the results (P=1.2400, I 2 =0%). Thus, we did a quantitative data synthesis (meta-analysis) by fixed-effects model. The outcome shows a statistically significant difference in favor of the combination group of XFZY and conventional drugs (RR: 1.20 [1.04, 1.38]; P = 0.01). It is suggested that XFZY plus conventional drugs had a better effect on improving ECG. (Table 3). Improvement of Life Quality Two trials [26, 28] reported the improvement of life quality of patients after 4-8 weeks of treatment with XFZY combined with conventional drugs. The statistical data show that XFZY plus conventional drugs was better than conventional drugs alone with regard to relieving body symptoms (MD: 8.03 [1.12, 14.96]) and promoting anginal stability (MD: 12.13 [4.61, 19.65]). Publication Bias Due to no sufficient number of trials, we failed to perform funnel plot to detect publication bias. Adverse Effect Five trials [23, 28] reported adverse effects relating to the treatment by XFZY combined with conventional drugs. The adverse effects included headache and nausea. The approximate rates of these adverse effects were 2% (6/265) and 1.5% (4/265) respectively. No severe adverse events 5 Page 5 of 14
were reported. Discussion This systematic review included 8 randomized trials and a total of 534 participants. The main findings of this systematic review were that XFZY combined with conventional drugs demonstrated potential effect on relieving symptoms of angina (RR: 1.26 [1.16, 1.38]; P < 0.00001) and improving ECG (RR: 1.20 [1.04, 1.38]; P = 0.01) compared to conventional drugs alone. XFZY as an adjunctive treatment to conventional drugs has good effects on treating patients with UA. However, the evidence remains weak due to the low-quality of the trials. Thus, available data are not adequate to draw a definite conclusion of combination therapy for UA. And the positive findings should be interpreted conservatively due to the following facts. Firstly, the quality of the included RCTs was generally low. (1) Randomization: all the included trials claimed randomization; however, 2 trials provided sufficient information on randomization [26, 28]. The other trials mentioned randomization but without further details, which did not allow a proper judgment of the conduct of the trials. It could lead to selection bias. (2) Blinding: only 1 trial [26] mentioned that they were single blind of subjects, but included no descriptions of the procedures. The rest studies were lack of any blinding method, either blinding of participants and personnel or blinding of outcome assessment. It could directly lead to performance bias due to patients and researchers being aware of the therapeutic interventions for the subjective outcome measures. (3) Sample size: none of trials had a pretrial estimation of sample size, which indicated the lack of statistical power to ensure appropriate estimation of the therapeutic effect. And all of the included trials were of single center. Sample size calculation should be conducted before enrollment. (4) Placebo controlled: 1 trial [26] had placebo control, which use A + B versus B + placebo of A ; however, the rest included trials used A + B versus B design which patients were randomized to receive XFZY plus conventional drugs treatment versus conventional drugs control treatment without a rigorous control for placebo effect. Consequently, positive conclusions would be draw due to nonspecific placebo effects. (5) Analysis of data: only 1 trial [26] had reported the dropouts, but without the intention-to-treat analysis. Therefore, the positive findings should be interpreted conservatively. It could lead to attrition bias. Nevertheless, there were 2 trials [25, 26] conducted by 3-7 authors. The rest 6 trials were only conducted by one or two authors. It is difficult to accomplish an RCT which including randomization, allocation concealment, blinding and analysis by less than 3 doctors. It could also lead to performance bias [29-32]. Secondly, all the included trials used reduction of angina symptoms or ECG test as the main outcomes. There were only a few trials report the original data about the frequency and duration of chest pain or reduction of nitroglycerin dose, however it was indicated a substantial level of heterogeneity of these data, and meta-analysis did not be adopt. All the RCTs claimed that the positive effect of XFZY combined with conventional drugs is better than conventional drugs alone. Negative findings almost have not been reported. We tried to conduct extensive searches for unpublished material, but no unpublished negative studies were found, which could lead to publication bias. Thirdly, patients in UA should be treated carefully because the risk of acute MI and severe cardiac arrhythmias may increase and lead to sudden death. Indeed, none of the included trials reported the mortality rate or the incidence of complications. It is likely to require longer periods 6 Page 6 of 14
of treatment due to the duration of included trials only ranged from 1 to 8 weeks. Moreover, the severity of angina symptoms may exacerbate without reasonable treatment, thus a longer follow-up period with serial measurements of outcomes is suggested to determine the long-term efficacy of Chinese patent medicine [33-35]. Fourthly, the safety problem of integrative medicine therapy with both conventional western medicine and tradition medicine is generally concerned [36-37]. Herb-drug interaction is an important focus of this systematic review. There were 2 trials reported the adverse effect of XFZY in combination with conventional drugs. The main adverse effects included headache (6/265) and nausea (4/265). Considering that limited report of adverse events, conclusions on the safety of XFZY could not be drawn. Generally, as the quality of 8 trials reviewed and included in meta-analysis were generally weak, further high quality trials are needed to assess the effectiveness of XFZY combined with conventional drugs in treating UA. To improve the trial design quality, future researchers should follow the basic guidelines for reporting clinical trials such as the CONSORT statement, and treatment process should be monitored rigorously and reported appropriately in the future clinical trials[38-42]. Conclusion Our systematic review suggest that XFZY in combination with conventional drugs may have good effect on reducing angina symptoms and improving ECG with few side effects for patients with UA. However, the definite conclusion cannot be drawn due to the low quality of included trials. More rigorously designed, large-sample, randomize controlled trials should be performed in the future. Conflicts of Interests All authors declare that they have no conflicts of interests. Acknowledgment The current work was partially supported by the National Basic Research Program of China (973 Program, No. 2003CB517103) and the National Natural Science Foundation Project of China (No. 90209011). Author contributions Jie Wang, X. Xiong contributed equally to this paper. Correspondence should be addressed to X. Yang (avill1988@126.com). References 1. Bernard R, Corday E, Eliasch H, and Gonin A et al, Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, The Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature, Circulation, vol. 59, pp.607-609, 1979. 2. Braunwald E, Morrow DA, Unstable angina: is it time for a requiem? Circulation, vol. 127, pp. 2452-2457, 2013. 3. Rosamond W, Flegal K, and Friday G et al, Heart Disease and Stroke Statistics-2007 Update: 7 Page 7 of 14
A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, vol. 115, pp. e5-92, 2007. 4. Pollack CV Jr, Braunwald E, 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: implications for emergency department practice, Ann Emerg Med, vol. 51, no. 5, pp. 591-606, 2007. 5. Wiviott SD, Braunwald E, Unstable angina and non-st-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care, Ann Emerg Med, vol. 70, no. 3, pp. 525-532, 2004. 6. Zavecz JH, Bueno O, Pharmacologic therapy of angina pectoris, J La State Med Soc, vol. 147, no. 5, pp. 208-210, 213-216, 1995. 7. Taggart D, Tailor treatment to the patient in stable angina, Practitioner, vol. 255, no. 1744, pp. 25-28, 2011. 8. K. J. Chen, H. Xu, The integration of traditional Chinese medicine and Western medicine Institute for clinical systems improvement, European Review, vol. 11, no. 2, pp. 225-235, 2003. 9. H. A. Tindle, R. B. Davis, R. S. Phillips, and D.M. Eisenberg, Trends in use of complementary and alternative medicine by US adults: 1997 2002, Alternative Therapies, Health and Medicine, vol. 11, no.1, pp. 42-49, 2005. 10. D. Eisenberg, Reflections on the past and future of integrative medicine from a lifelong student of the integration of Chinese and western medicine, Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 3-5, 2011. 11. S. Jun, W. Y. Chen, and K. J. Chen, et al, A Microarray Analysis of Angiogenesis Modulation Effect of Xuefu Zhuyu Decoction on Endothelial Cells, Chin J Intergr Med, vol. 18, no. 7, pp. 502-506, 2012. 12. Q. Y. Zhang, Q. L. Wang, and J. F. Su, et al., Angiogenesis Effects of Xuefu Zhuyu Decoction and VEGF Protein Expression of Rats with Acute Myocardial Ischemia, Chinese Journal of Information on TCM, vol. 18, no.2, pp. 53-54, 2011. 13. H. J. Cui, H. Y. He, and Z. H. Xing, Systematic Review and meta-analysis of Xuefu Zhuyu Decoction in patients with unstable angina, Journal of Emergency in Traditional Chinese Medicine, vol. 20, no.7, pp. 1071-1075, 2011. 14. G. H. Zheng, J. F. Chu, and J. P. Liu, Systematic Review of Xuefu Zhuyu Capsule for angina pectoris in patients with coronary heart disease, Journal of Traditional Chinese Medicine, vol. 53, no. 2, pp. 117-122, 2012. 15. X. M. Song, Meta-analysis of Xuefu Zhuyu Decoction combined with asprin and isosorbide mononitrate for angina pectoris in patients with coronary heart disease, The Journal of Practical Medicine, vol. 26, no. 14, pp. 2633-2636, 2010. 16. C. L. Wang, Q. W, and S. L. Wang, Meta-analysis of modefied Xuefu Zhuyu Decoction in patients with coronary heart disease, Journal of Liaoning University of TCM, vol.13, no.11, pp. 5-9, 2011. 17. American College of Cardiology and American Heart Association, ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations, Circulation, vol. 102, pp. 1193 1209, 2000. 8 Page 8 of 14
18. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease, Report of the joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature, Circulation, vol. 3, pp. 607 609, 1979. 19. Ministry of health of the People s Republic of China, Clinical research guidelines for new traditional Chinese drug, August, 42-44, 1993. 20. J. P. T. Higgins and S. Green, Corchrane Reviewers Handbook 5.1.0 [updated March 2011], Review Manager (RevMan) [Computer program]. Version 5.1.0. 21. W. D. Qiu, C. Y. Yang, Clinical observation of Xuefu Zhuyu Decoction for unstable angina and effect of Hs-CRP in patients with coronary heart disease, Clinical Journal of Chinese Medicine, vol. 4, no. 6, pp. 14-15, 2012. 22. Z. X. Zhang, X. P. Song, Clinical observation of modified Xuefu Zhuyu Decoction for unstable angina in 50 cases, Hebei Journal of Traditional Chinese Medicine, vol. 28, no.4, pp. 275-276, 2006. 23. F. Q. Wang, Clinical observation of modified Xuefu Zhuyu Decoction for unstable angina in patients with coronary heart disease, Journal of Changchun University of Traditional Chinese Medicine, vol. 27, no. 1, pp. 87-88, 2011. 24. B. R. Zhao, J. P. Feng, and Q. Qin, et al, Protective Effect of Xuefu Zhuyu Capsule for endothelial cells due to angina pectoris in patients with coronary heart disease, National General Medical Journal of China, vol. 3, no. 9, pp. 791-792, 2002. 25. Y. R. Li, H. F. Zhang, and J. Du, et al, Clinical observation of Xuefu Zhuyu Capsule for unstable angina in patients with coronary heart disease, Journal of Liaoning University of Traditional Chinese Medicine, vol. 10, no. 11, pp. 103-104, 2008. 26. F. Y. Chu, J. Wang, and K. W. Yao, et al, Effect of Xuefu Zhuyu Capsule on the Symptoms and Signs and Health-related Quality of Life in the Unstable Angina Patients with Blood-stasis Syndrome after Percutaneous Coronary Intervention: A Randomized Controlled Trial, Chin J Intergr Med, vol. 16, no. 5, pp. 399-406, 2010. 27. X. Y. Wang, Y. Lou, Combination of Xuefu Zhuyu Decoction with western medicine for unstable angina in 56 cases with coronary heart disease, Tianjin Journal of Traditional Chinese Medicine, vol. 26, no. 6, pp. 521, 2008. 28. G. L. Zheng, S. H. Wang, Clinical Effect and Mechanism of Xuefu Zhuyu Capsule in Treating Unstable Angina Pectoris, Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 1, pp. 65-69, 2009. 29. Wang Q, Wu T, Chen X, et al., Puerarin injection for unstable angina pectoris, Cochrane Database Syst Rev, vol. 19, no. 3, CD004196, 2006. 30. Andraws R, Berger JS, Brown DL, Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials, Cochrane Database Syst Rev, vol. 293, no. 21, pp. 2641-7, 2005. 31. Zhang JH, Shang HC, Gao XM, et al., Compound Salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review, Med Sci Monit, vol. 14, no. 1, pp. 1-7, 2008. 32. Wu T, Harrison RA, Chen X, et al., Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris, Cochrane Database Syst Rev, vol. 18, no. 4, CD004474, 2006. 33. Wang J, Yang X, Chu F, et al., The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after 9 Page 9 of 14
percutaneous coronary intervention: a randomised controlled clinical trial, Evid Based Complement Alternat Med, 2013:896467. doi: 10.1155/2013/896467, 2013. 34. Wang J, Yang X, Feng B, et al., Is yangxue qingnao granule combined with antihypertensive drugs, a new integrative medicine therapy, more effective than antihypertensive therapy alone in treating essential hypertension?, Evid Based Complement Alternat Med, 2013:540613. doi: 10.1155/2013/540613, 2013. 35. Wang J, Yao K, Yang X, et al., Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials, Evid Based Complement Alternat Med, 2012:714805. doi: 10.1155/2012/714805, 2012. 36. Food and Drug Administration of the People's Republic of China, Guidelines for clinical research in treatment of Qi stagnation of Chest with Chinese medicine (Angina pectoris)- Guidelines for clinical research with Chinese medicine/new medicine, China Medical Science and Technology Press, pp. 68-73, 2002. 37. J. Hu, J. H. Zhang, and W. Zhao, et al., Cochrane systematic reviews of Chinese herbal medicines: an overview, Plos one, vol. 6, pp. 1371, 2011. 38. Turner L, Shamseer L, Altman DG, et al., Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review, Syst Rev, vol. 1, no. 60, doi: 10.1186/2046-4053-1-60, 2012. 39. Turner L, Shamseer L, Altman DG, et al., Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals, Cochrane Database Syst Rev, vol. 14, no. 11, doi: 10.1002/14651858, 2012. 40. X. J. Xiong, X. C. Yang, W. Liu, B. Feng, J. Z. Ma, X. L. Du, P. Q. Wang, F. Y. Chu, J. Li, and J. Wang, Banxia baizhu tianma decoction for essential hypertension: a systematic review of randomized controlled trials, Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 271462, 10 pages, 2012. doi:10.1155/2012/271462. 41. X. J. Xiong, X. C. Yang, B. Feng, W. Liu, L. Duan, A. Gao, H. X. Li, J. Z. Ma, X. L. Du, N. Li, P. Q. Wang, K. L. Su, F. Y. Chu, G. H. Zhang, X. K. Li, and J. Wang, Zhen gan xi feng decoction, a traditional Chinese herbal formula, for the treatment of essential hypertension: a systematic review of randomized controlled trials, Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 982380, 9 pages, 2013. 42. Smith SM, Chang RD, Pereira A, et al., Adherence to CONSORT harms-reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review, Pain, vol. 153, no. 12, pp. 2415-2421, 2012. 10 Page 10 of 14
Included Eligibility Screening Identification Records identified through database searching (n =609) Records after duplicates removed (n =252) Records screened (n =458) Full-text articles assessed for eligibility (n =53) Studies included in meta-analysis (n =8) Additional records identified through other sources (n = 1) Figure 1. Flow-chart of Study Search and Selection Records excluded (n =405) Full-text articles excluded, with reasons (n =45): Non RCTs (n =3) Duplicated publication (n =3) Diagnosis uncertainty (n =8) Inappropriate control (n =15) Ineligible data extraction (n =5) Patients complicated with serious medical conditions (n =11) 11 Page 11 of 14
Table1. The characteristics of included RCTs of XFZY for UA Study ID Sample Diagnosis Age Intervention Control Course Outcome (T/C) standard group group (week) measures Qiu and Yang 2012 [21] Zhang and Song 2006 [22] 30/30 1979 40-78 XFZY+conventional drugs conventional drugs 2 RAS ISFC/WHO 50/50 2002 35-79 XFZY conventional drugs 3 RAS, ECG ACCF/AHA Accepted Manuscrip Notes: XFZY: XueFu Zhuyu Capsule; RAS: Reduction of angina symptoms + conventional drugs Wang 2011 [23] 40/40 2002 60.3±8.3 XFZY conventional drugs 4 RAS, ACCF/AHA + conventional drugs adverse event Zhao et al [24] 30/31 1979 46-65 XFZY conventional drugs 1 RAS Li et al 2008 [25] Chu et al 2009 [26] ISFC/WHO + conventional drugs 30/30 2002 50-70 XFZY + isosorbide isosorbide dinitrate, 4 RAS, ECG ACCF/AHA dinitrate, aspirin aspirin 28/29 2002 50-70 XFZY conventional drugs 4 RAS, ACCF/AHA + conventional drugs + placebo of XFZY Life quality Wang and Lou 28/28 1979 Not clear XFZY conventional drugs 2 RAS, ECG, 2009 [27] Zheng and Wang 2009 [28] ISFC/WHO 30/30 1979 ISFC/WHO + conventional drugs 40-82 XFZY conventional drugs 8 RAS, ECG + conventional drugs 1 Page 12 of 14
Table 2. Analyses of reduction of angina symptoms Trials Intervention (n/n) Control (n/n) RR [95% CI] P Value XFZY plus conventional drugs versus conventional drugs 1 26/30 19/30 1.37 [1.01, 1.86] 0.04 XFZY plus conventional drugs versus conventional drugs 1 47/50 41/50 1.15 [0.99, 1.33] 0.07 XFZY plus conventional drugs versus conventional drugs 1 37/40 30/40 1.23 [1.01, 1.51] 0.04 XFZY plus conventional drugs versus conventional drugs 1 28/30 21/31 1.38 [1.06, 1.79] 0.02 XFZY plus isosorbide dinitrate and aspirin versus isosorbide dinitrate and aspirin Accepted Manuscrip 1 28/30 24/30 1.17 [0.95, 1.43] 0.14 XFZY plus conventional drugs versus conventional drugs 1 25/28 18/28 1.39 [1.02, 1.88] 0.03 XFZY plus conventional drugs versus conventional drugs 1 28/30 21/30 1.33 [1.04, 1.72] 0.03 Table 3. Analyses of improvement of ECG Trials Intervention (n/n) Control (n/n) RR [95% CI] P Value XFZY plus conventional drugs versus conventional drugs 1 36/50 30/50 1.20 [0.90, 1.60] 0.21 XFZY plus isosorbide dinitrate and aspirin versus isosorbide dinitrate and aspirin 1 27/30 23/30 1.17 [0.93, 1.48] 0.17 XFZY plus conventional drugs versus conventional drugs 1 24/28 20/28 1.20 [0.91, 1.59] 0.20 XFZY plus conventional drugs versus conventional drugs 1 23/30 19/30 1.21 [0.86, 1.69] 0.27 2 Page 13 of 14
Conflicts of Interests All authors declare that they have no conflicts of interests. 3 Page 14 of 14